News
FDA Approves CAR-T Immunotherapy for 2nd Indication
Approval for a personalized cellular therapy for the treatment of adult patients with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy.
Read moreNews
FDA Approval Recommendation for CAR T-Cell Therapy
FDA advisory committee unanimously approves first personalized cellular therapy developed at Penn for pediatric and young adult leukemia.
Read moreBlog
Following A Patient Story From Transfusion Medicine to Hemepath Rotations
When I started my pathology residency, I never expected to have such a moving patient experience.
read moreNews
Clinical Trial for Personalized Immunotherapy in Glioblastoma
Results from nine patients with brain tumor reported at AACR.
Read moreNews
Partnership to Produce Gene Therapies
Plans to open a 145,000-square-foot cell and gene therapy manufacturing plant at the Philadelphia Navy Yard.
Read moreNews
New Patents for Pathology Research Team
Issued for technologies in pioneering personalized cellular therapy CTL019 for patients with leukemia and lymphoma.
Read more
